

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CON5

SERIAL NO.: Not yet known

10/057,630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Herewith

GROUP: Not Yet Known

1639

J1960 U.S. PTO
10/057,630
01/05/92

U.S. PATENT DOCUMENTS

SECRET DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA		5	8	5	9	2	5	7	01/12/99	Talley	548	247	08/14/98
AB		5	8	6	3	9	2	2	01/26/99	Mayer, et al.	514	270	07/02/99
AC		5	8	4	0	7	3	1	11/24/98	Mayer, et al.	514	289	08/02/95
AD		5	8	6	9	4	9	8	02/09/99	Mayer, et al.	514	282	07/07/97
AE		5	8	6	1	4	1	9	01/19/99	Dube, et al.	514	334	07/11/97
AF		5	7	8	9	4	1	3	08/04/98	Black, et al.	514	255	01/21/97
AG		5	6	0	4	2	6	0	02/18/97	Guay, et al.	514	605	11/04/93
AH		5	4	5	8	8	7	9	10/17/95	Singh, et al.	424	400	09/30/94
AI		5	5	1	6	8	0	3	05/14/96	Raffa	514	570	03/01/95
AJ		5	8	4	3	4	6	8	12/01/98	Burkoth, et al.	424	448	05/13/96

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AK	Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX-2) By NSAIDs: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Pairet, et al., Inflammopharmacology 4: 61-70, (1996).
AL	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. European J. Pharm 355 pp 211-217, (1998).
AM	Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998).
AN	Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996).
AO	Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. And Applied Skin Phys. 11:273-278, (1998).
AP	Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cartiona Hay and Jacqueline de Belleruche, Neuro Report 8, 1249-1251, (1997).
AO	The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996).
AR	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47:79-85, (1998).
AS	Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, Vol. 16, No. 2, pp. 181-206, (1996).

EXAMINER

DATE CONSIDERED

8/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON5		SERIAL NO.: Not Yet Known 10/057,630	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: Not Yet Known		GROUP: Not Yet Known 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	BL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BM	Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. Vol. 12 pp. 1063-1073 (1998).					
	BN	Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With An Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996)					
	BO	Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).					
	BP	Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15, (1996).					
	BQ	Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Visceronoception Induced by Phenylquinone, Hidenobu Kusuha, et al. Prostaglandins 55: 43-49, (1998).					
	BR	Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. D. Dirig, et al. J. Pharmacol. And Experimental Therapeutics Vol. 285, No. 3, pp 1031-1038.					
	EXAMINER				DATE CONSIDERED 5/26/04		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CON5

SERIAL NO.: Not Yet Known

10/057, 630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MA	DA	5	4	7	4	9	9	5	12/12/95	Ducharme et al.	514	241	01/10/94
	DB	5	6	9	1	3	7	4	11/25/97	Black et al.	514	473	05/18/95
	DC												
	DD												
	DE												
	DF												
	DG												
	DH												
	DI												
	DJ												
	DK												

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	DL													
	DM													
	DN													
	DO													
	DP													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DQ	
	DR	
	DS	

EXAMINER

DATE CONSIDERED

8/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CON5

SERIAL NO.: Not Yet Known

10/057, 630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MA	EA	3	8	0	0	0	4	1	03/26/74	Miller, et al.	424	273	03/02/71
	EB	4	3	2	2	4	2	7	03/30/82	Buyinski, et al.	424	260	04/16/81
	EC	4	3	3	8	3	2	4	08/06/82	Gardocki	424	266	03/17/81
	ED	4	4	0	4	2	1	0	09/13/83	Schmidt	424	260	06/30/82
	EE	4	4	0	7	8	0	4	10/04/83	Schmidt	424	260	06/30/82
	EF	4	4	0	7	8	0	5	10/04/83	Schmidt	424	260	06/30/82
	EG	4	4	6	4	3	7	6	08/07/84	Sunshine, et al.	424	253	10/11/83
	EH	4	4	8	6	4	3	6	12/04/84	Sunshine, et al.	424	253	03/11/83
MA	EI	4	4	8	9	0	8	0	12/18/84	Lomen	424	260	12/06/82

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
MA	EJ	2	0	2	3	3	4	9	02/18/91	Canada	A61K	31/44		
	EK	0	2	7	4	8	4	5	07/20/88	EP (A1)	A61K	31/19		
MA	EL	0	3	8	8	1	2	5	09/19/90	EP (A1)	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MA	EM	Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. <i>Arzneim-Forsch./Drug Res.</i> 46 (II) 57-63 (1996).											
MA	EN	Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G.K. Vlok, et al. <i>Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg.</i> pp 3-6, (1987).											
	EO												
	EP												
	EQ												
	ER												

EXAMINER

DATE CONSIDERED

8/24/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CON5

SERIAL NO.: Not Yet Known

10/057,630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>W</i>	FA	4	5	6	7	1	8	3	01/28/86	Sunshine, et al.	514	264	12/12/83
	FB	4	5	6	9	9	3	7	02/11/86	Baker, et al.	514	282	02/11/83
	FC	4	5	7	1	4	0	0	02/18/86	Arnold	514	282	12/18/84
	FD	4	5	8	7	2	5	2	05/06/86	Arnold	514	282	12/18/84
	FE	4	6	1	9	9	3	4	12/28/86	Sunshine, et al.	514	277	07/08/85
	FF	4	6	9	0	9	2	7	09/01/87	Voss, et al.	514	282	02/03/86
	FG	4	8	3	9	1	7	6	06/13/89	Pakhania, et al.	424	465	12/08/87
	FH	4	8	4	4	9	0	7	07/04/89	Elger, et al.	424	465	08/14/86
	FI	4	9	2	7	8	5	4	05/22/90	Sunshine, et al.	514	570	08/21/89
	FJ	5	1	6	4	3	9	8	12/17/92	Sims, et al.	514	282	04/01/91
	FK	5	1	9	0	9	4	7	03/02/93	Riess, et al.	514	282	08/16/91
<i>W</i>	FL	5	2	4	0	6	9	4	08/31/93	Gwaltney, Jr.	424	45	12/19/91

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
<i>W</i>	FM	0	0	6	8	8	3	8	06/25/82	EP (A1)	A61K	31/485		
<i>W</i>	FN	0	0	8	8	8	3	8	06/25/82	EP (B1)	A61K	31/485		
<i>W</i>	FO	2	0	8	1	6	0	4	05/01/95	Canada	A61K	031/135		
	FP													
	FD													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	FR	
	FS	
	FT	

EXAMINER

DATE CONSIDERED

8/24/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CONS

SERIAL NO.: Not Yet Known

10/057,630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ML	GA	5 4 0 9 9 4 4	04/25/95	Black, et al.	514	359	03/12/93
	GB	5 4 3 6 2 6 5	06/25/95	Black, et al.	514	420	11/12/93
	GC	5 5 1 0 3 6 8	04/23/96	Lau, et al.	514	419	05/22/95
	GD	5 5 2 1 2 1 3	05/28/96	Prasit, et al.	514	443	08/29/94
	GE	5 5 5 0 1 4 2	08/27/96	Ducharme et al.	514	365	05/08/95
	GF	5 5 5 2 4 2 2	09/03/96	Gauthier, et al.	514	368	01/11/95
	GG	5 6 0 4 2 5 3	02/18/97	Lau, et al.	514	415	05/22/95
ML	GH	5 6 3 9 7 8 0	06/17/97	Lau, et al.	514	419	05/22/95

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	GI							
	GJ							
	GK							
	GL							
	GM							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GN	Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, Supplement 2 (1996).
	GO	
	GP	
	GQ	
	GR	

EXAMINER



DATE CONSIDERED

5/24/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079CON5SERIAL NO.: Not Yet Known
10/057, 630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known
1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HD						
	HE						
	HF						
	HG						
	HH						
	HI						
	HJ						
	HK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	HL							
	HM							
	HN							
	HO							
	HP							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ml	HQ	Rorarius et al., "Non-Steroidal Anti-Inflammatory Drugs for PostOperative Pain Relief," Curr. Opin. In Anaesthesiology, 7, 358-362). (1994)
f	HR	Hansen et al. "Pharmacokinetics and Drug Input Characteristics for a Disclufenac-Codeine Phosphate Combination Following Oral and Rectal Administration," Arzneim.-Forsch./Drug Res., 46(II), Nr. 1,57-63. (1996)
	HS	Merck Index, Twelfth Edition, Merck & Co. Publishers, page 1194. (1996)
nr	HT	Goodman and Gillman's: Pharmaceutical Basis of Therapeutics, "Chapter 22: Opioid Analgesics and Antagonists", MacMillan Publishing Co., Inc., pp-494-497, esp. Table 22-1, p. 496. (1980)

EXAMINER

DATE CONSIDERED

8/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079US

SERIAL NO.: 09/154,354

10/057,630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:
September 17, 1998

GROUP: 1627

1639

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
													YES	NO
AA	0	6	5	4	2	6	3	05/24/95	EP (A1)	A61K	31/135			
	AB	0	6	5	4	2	6	3	05/24/95	EP (B1)	A61K	31/135		
	AC	9	7	1	7	9	7	8	05/22/97	WO	A61K	33/00		
	AD	9	7	2	5	9	8	8	07/24/97	WO	A61K	31/495		
	AE	9	7	3	2	8	5	7	09/12/97	WO	C07D	241/104		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Dray et al. New Pharmacological Strategies for Pain Relief. <u>Annual Review of Pharmacology & Toxicology</u> , 36, pp. 253-280. (1996).
AG	Brasseur, L. Revue des therapeutiques pharmacologiques actuelles de la douleur. <u>Drugs</u> , 53 Suppl 2, pp. 10-17. (1997)
AH	Rang et al. New molecules in analgesia. <u>British Journal of Anesthesia</u> , 75, pp. 145-156 (1995)
AI	Beaver, WT. Combination Analgesics. <u>American Journal of Medicine</u> , 77 (Suppl 3A), pp. 38-53. (1984).
AJ	Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In <u>Evaluation and Treatment of Chronic Pain</u> , 2 nd ed., William & Wilkins pp. 363-383. (1992).
AK	Goodman & Gilman's. <u>The Pharmacological Basis of Therapeutics</u> , 9 th Edition. McGraw-Hill, New York, pp 535 and 551-552.
AL	Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. <u>Pain</u> , 73, 3 pp. 401-406. (1997).
AM	Etches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. <u>Anesthesia & Analgesia</u> , 81 (6), pp. 1175-1180. (1995).
AN	Hodsmen et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. <u>Anaesthesia</u> , 42(9), pp. 1005-1008. (1987).
AO	Kaasalainen et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. <u>Pain</u> , 70, 2-3, pp. 175-183. (1997).
AP	Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. <u>Journal of Clinical Pharmacology</u> , 37 (10), pp. 908-915. (1997).
AQ	Insel. Chapter 27: Analgesic-Antipyretic and Anti-Inflammatory Agents. In Hardman, ed., <u>Goodman & Gilman's The Pharmacological Basis of Therapeutics</u> , 9 th Edition. McGraw-Hill, New York, pp. 654-655. (1996).
AR	Polisson. Non-steroidal Anti-inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. <u>The American Journal of Medicine</u> , 100 (Suppl 2A), pp. 2A-31S - 2A-36S. (1996).
AS	Vane, J. Towards a better aspirin. <u>Nature</u> , 367, pp. 215-216. (1994).
AT	Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. <u>Journal of Clinical Rheumatology</u> , 2 (3), pp. 135-140. (1996).

EXAMINER



DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
DEC 11 4 1998
TECH CENTER 1600/2900

FORM PTO-1449 (REV. 7-90)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09454,354 101057,630	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: September 17, 1998		GROUP: 1027 1639	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BA	Van Ryn et al. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. <u>Expert Opinion On Investigational Drugs</u> . pp. 609-614. (1997).						
BB	Vane et al. New insights into the mode of action of anti-inflammatory drugs. <u>Inflammation Research</u> . 44, (No.1), pp 1-10 (1995).						
BC	Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. <u>British Journal of Rheumatology</u> . 34, Abstract Suppl. 1, p. 48. (1995). Abstract.						
BD	Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. <u>Journal of Rheumatology</u> . Vol. 24, Suppl 49, pp. 20-24. (1997).						
BE	Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. <u>Neuropharmacology</u> Vol. 33, pp. 1609-1611. (1994).						
BF	Donnelly et al. COX-II Inhibitors - a new generation of safer NSAIDS? <u>Alimentary Pharmacology and Therapeutics</u> , 11, 2, pp. 227-236. (1997).						
BG	Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. <u>Gastroenterology</u> , 112, 3, pp. 1000-1016. (1997).						
BH	Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. <u>J Rheumatology</u> , 24, Suppl. 47, pp. 32-39. (1997).						
BI	Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Musculoskeletal Disease: A Canadian Consensus. <u>Canadian Medical Association Journal</u> , 155, 1, pp. 77-88. (1996).						
BJ	Mehlisch et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. <u>Journal of Clinical Pharmacology</u> , 37, 9, 863. (1997). Abstract.						
BK	Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointestinal Toxicity. <u>Gut</u> , 39, Suppl. 3, A151. (1996). Abstract.						
BL	Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). <u>Journal Of Medicinal Chemistry</u> , 40(9), 1347-65. (1997).						
BM	Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. <u>Journal Of Rheumatology</u> , 24 Suppl 49, pp. 9-14. (1997).						
BN							
BO							
BP							
BQ							
BR							
BS							
BT							
EXAMINER <i>[Signature]</i>				DATE CONSIDERED <i>8/20/01</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED
DEC 04 2000
TECH CENTER 1600-2900

FORM PTO-1449 (REV. 1-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 091134,354 <u>10/057,630</u>							
 LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.									
				FILING DATE: September 17, 1998		GROUP: 1027 <u>1039</u>							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA												
	AB												
	AC												
	AD												
	AE												
	AF												
	AG												
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	0	7	3	4	2	7	5	11/04/1997	Australia	C07D	261/08	
	AI												
	AJ												
	AK												
	AL												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	AM												
	AN												
	AO												
	AP												
	AQ												
	AR												
	AS												
EXAMINER 								DATE CONSIDERED <u>8/26/04</u>					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
DEC 02 2002
TECH CENTER 1600/2900